Key result
Newly diagnosed T2DM and prediabetes are linked to ~6-point lower FMD versus healthy controls.
Why the study?
The DNA repair enzyme OGG1 is implicated in endothelial homeostasis, and endothelial dysfunction is an early vascular manifestation of prediabetes and type 2 diabetes. However, clinical data on circulating serum OGG1 levels and their association with endothelial dysfunction remain limited.
Cross-Sectional (n=88)
No
Circulating serum OGG1 levels and brachial artery flow-mediated dilation are significantly reduced as early as the prediabetic stage and in newly diagnosed treatment-naive type 2 diabetes, with lower OGG1 levels correlating with worse endothelial function and higher glycemic indices.
Answers are grounded in this paper and cite their sources.
Lower OGG1 with impaired FMD in prediabetes and new T2DM may signal early vascular risk; leaves open OGG1 utility for endothelial assessment.
Background The DNA repair enzyme 8-oxoguanine DNA glycosylase-1 (OGG1) plays a key role in repairing oxidative DNA damage and has been implicated in endothelial homeostasis. Endothelial dysfunction is an early manifestation of vascular injury in prediabetes and type 2 diabetes, but clinical data on circulating serum OGG1 levels and their association with endothelial dysfunction remain limited. We investigated serum OGG1 levels and endothelial function assessed by flow-mediated dilation (FMD) in individuals with type 2 diabetes, prediabetes, and normoglycemic controls, and evaluated the relationship between serum OGG1 levels, glycemic parameters, and endothelial dysfunction. Methods This cross-sectional study included 88 participants: 29 with newly diagnosed, treatment-naive type 2 diabetes mellitus (T2DM), 30 with prediabetes, and 29 normoglycemic controls. Brachial artery FMD was measured by high-resolution ultrasonography, and serum OGG1 levels were measured by enzyme-linked immunosorbent assay. Multivariable linear regression was used to identify independent determinants of FMD. Results Serum OGG1 levels differed significantly among the groups, with lower levels in both T2DM and prediabetes than in controls (medians 570.8, 626.9, and 914.9 ng/L, respectively; p = 0.008). FMD was significantly lower in T2DM (4.40 ± 2.56%) than in prediabetes (8.15 ± 3.27%) and controls (10.75 ± 2.81%) ( p < 0.001). In univariate analysis, OGG1 correlated positively with FMD ( r = 0.315, p = 0.003) and negatively with HbA1c and fasting glucose (all p ≤ 0.002). In multivariable analysis, HbA1c (β=−0.475, p < 0.001), baseline brachial artery diameter (β=−0.448, p < 0.001), and male sex ( p = 0.010) were independent determinants of FMD. Conclusions Lower circulating serum OGG1 levels were observed even in prediabetes, not only in overt type 2 diabetes. Glycemic status may be an important factor influencing circulating OGG1 levels and their relationship with endothelial function. Further longitudinal studies are warranted to clarify the role of OGG1 in dysglycemia. Clinical trial number Not applicable.
No takes yet. Share an insight, caveat, or question.
Kutuk et al. (2026) conducted a cross-sectional in Prediabetes and newly diagnosed, treatment-naive type 2 diabetes mellitus (n=88). Newly diagnosed treatment-naive type 2 diabetes and prediabetes vs. Normoglycemic healthy controls was evaluated on Brachial artery flow-mediated dilation (FMD, %) (MD -6.35%, p=<0.001). Newly diagnosed T2DM and prediabetes exhibited lower serum OGG1 and FMD than controls.
Synapse has enriched 10 related papers. Consider them for comparative context: